person · Reporting owner

Lukatch Heath

Disclosed activity across 4 companies

Tapewire entity: 37683
SEC CIK: 0001596385

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Inogen IncINGN · Entity 2083	Director	May 10, 2021	May 12, 2021
Vaxcyte, Inc.PCVX · Entity 1164	Director	June 15, 2026	June 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inogen Inc

Report date May 10, 2021 · Filed May 12, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,775	Reported balance After 2021-05-10 transaction · row 1 1 source row Row 1 · 2021-05-10 · Grant · Acquired 2,754 · Balance 12,775 F1: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date.

Vaxcyte, Inc.

Report date June 15, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,481	Reported balance After 2026-06-15 transaction · row 1 1 source row Row 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 19,481 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15	Direct	11,389	Reported balance After 2026-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Flexion Therapeutics Inc

Report date November 19, 2021 · Filed November 19, 2021

Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2025-06-16	Direct	Reported balance After 2021-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2026-06-09	Direct	Reported balance After 2021-11-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21	Direct	Reported balance After 2021-11-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09	Direct	Reported balance After 2021-11-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23	Direct	Reported balance After 2021-11-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.

F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.

F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

Satsuma Pharmaceuticals, Inc.

Report date June 08, 2023 · Filed June 08, 2023

Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.97	Direct	Reported balance After 2023-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60	Direct	Reported balance After 2023-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46	Direct	Reported balance After 2023-06-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-08 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.

F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2026 Filed Jun 16, 2026 20:15 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantStock Option (right to buy) · Derivative	11,389	$0.00 Strike: $49.56	$0.00	Disclosure SEC source: 0001596385-26-000002 · wk-form4_1781640912.xml · derivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 11,389 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
June 15, 2026 Filed Jun 16, 2026 20:15 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantCommon Stock	2,265	$0.00	$0.00	Disclosure SEC source: 0001596385-26-000002 · wk-form4_1781640912.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,481 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
June 12, 2025 Filed Jun 16, 2025 22:09 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantStock Option (right to buy) · Derivative	15,372	$0.00 Strike: $34.46	$0.00	Disclosure SEC source: 0001596385-25-000004 · wk-form4_1750111759.xml · derivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,372 Underlying: Common Stock · 15,372 shares Expires 2035-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
June 12, 2025 Filed Jun 16, 2025 22:09 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantCommon Stock	3,041	$0.00	$0.00	Disclosure SEC source: 0001596385-25-000004 · wk-form4_1750111759.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,216 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
April 08, 2025 Filed Apr 10, 2025 12:06 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	1,000	$0.00 Strike: $21.49	$0.00	Disclosure SEC source: 0001649094-25-000051 · wk-form4_1744286786.xml · derivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,000 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
April 08, 2025 Filed Apr 10, 2025 12:06 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001649094-25-000051 · wk-form4_1744286786.xml · derivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
April 08, 2025 Filed Apr 10, 2025 12:06 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	1,000	$21.49	$21,490.00	Disclosure SEC source: 0001649094-25-000051 · wk-form4_1744286786.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 08, 2025 Filed Apr 10, 2025 12:06 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	6,000	$16.00	$96,000.00	Disclosure SEC source: 0001649094-25-000051 · wk-form4_1744286786.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:09 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantStock Option (right to buy) · Derivative	7,250	$0.00 Strike: $72.51	$0.00	Disclosure SEC source: 0001649094-24-000012 · wk-form4_1718050182.xml · derivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:09 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantCommon Stock	1,550	$0.00	$0.00	Disclosure SEC source: 0001649094-24-000012 · wk-form4_1718050182.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,175 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:40 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-002320 · form4-02022024_090210.xml · derivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 5,000 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:40 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	5,000	$71.50	$357,500.00	Disclosure SEC source: 0001415889-24-002320 · form4-02022024_090210.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,625 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023. Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:40 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	5,000	$16.00	$80,000.00	Disclosure SEC source: 0001415889-24-002320 · form4-02022024_090210.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:12 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	4,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-002058 · form4-01312024_090128.xml · derivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 4,000 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:12 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	4,000	$67.50	$270,000.00	Disclosure SEC source: 0001415889-24-002058 · form4-01312024_090128.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,625 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:12 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	4,000	$16.00	$64,000.00	Disclosure SEC source: 0001415889-24-002058 · form4-01312024_090128.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:26 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	13,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-24-000783 · doc4.xml · derivative · entry 6 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 13,000 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:26 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	291	$65.19	$18,970.87	Disclosure SEC source: 0001209191-24-000783 · doc4.xml · nonDerivative · entry 5 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,625 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $65.12 to $65.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:26 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	4,164	$64.28	$267,661.92	Disclosure SEC source: 0001209191-24-000783 · doc4.xml · nonDerivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,916 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $64.015 to $64.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:26 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	7,444	$63.55	$473,081.09	Disclosure SEC source: 0001209191-24-000783 · doc4.xml · nonDerivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,080 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.01 to $64.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:26 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	1,101	$62.85	$69,201.15	Disclosure SEC source: 0001209191-24-000783 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,524 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:26 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	13,000	$16.00	$208,000.00	Disclosure SEC source: 0001209191-24-000783 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2023 Filed Jun 15, 2023 21:55 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $53.08	$0.00	Disclosure SEC source: 0001209191-23-037508 · doc4.xml · derivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
June 13, 2023 Filed Jun 15, 2023 21:55 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-23-037508 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
June 08, 2023 Filed Jun 8, 2023 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	Disposition to issuerStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $3.46	$0.00	Disclosure SEC source: 0000899243-23-014878 · doc4.xml · derivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document
June 08, 2023 Filed Jun 8, 2023 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	Disposition to issuerStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $4.60	$0.00	Disclosure SEC source: 0000899243-23-014878 · doc4.xml · derivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document
June 08, 2023 Filed Jun 8, 2023 16:31 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	Disposition to issuerStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $27.97	$0.00	Disclosure SEC source: 0000899243-23-014878 · doc4.xml · derivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document
January 10, 2023 Filed Jan 12, 2023 21:33 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	315	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-23-003152 · doc4.xml · derivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 315 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document
January 10, 2023 Filed Jan 12, 2023 21:33 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	82	$46.33	$3,798.85	Disclosure SEC source: 0001209191-23-003152 · doc4.xml · nonDerivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $46.29 to $46.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 10, 2023 Filed Jan 12, 2023 21:33 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	233	$46.04	$10,727.62	Disclosure SEC source: 0001209191-23-003152 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $45.27 to $46.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 10, 2023 Filed Jan 12, 2023 21:33 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	315	$16.00	$5,040.00	Disclosure SEC source: 0001209191-23-003152 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 12, 2022 Filed Dec 14, 2022 22:03 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	335	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-22-061256 · doc4.xml · derivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,315 Underlying: Common Stock · 335 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document
December 12, 2022 Filed Dec 14, 2022 22:03 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	319	$44.01	$14,039.29	Disclosure SEC source: 0001209191-22-061256 · doc4.xml · nonDerivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $43.745 to $44.43. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
December 12, 2022 Filed Dec 14, 2022 22:03 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	16	$42.37	$677.84	Disclosure SEC source: 0001209191-22-061256 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,444 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
December 12, 2022 Filed Dec 14, 2022 22:03 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	335	$16.00	$5,360.00	Disclosure SEC source: 0001209191-22-061256 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 10, 2022 Filed Nov 15, 2022 21:59 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionStock Option (right to buy) · Derivative	4,335	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-22-057030 · doc4.xml · derivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,650 Underlying: Common Stock · 4,335 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document
November 10, 2022 Filed Nov 15, 2022 21:59 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	4,000	$46.25	$185,000.00	Disclosure SEC source: 0001209191-22-057030 · doc4.xml · nonDerivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
November 10, 2022 Filed Nov 15, 2022 21:59 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	335	$44.74	$14,988.57	Disclosure SEC source: 0001209191-22-057030 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $44.51 to $45.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
November 10, 2022 Filed Nov 15, 2022 21:59 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	4,335	$16.00	$69,360.00	Disclosure SEC source: 0001209191-22-057030 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 26, 2022 Filed Oct 26, 2022 21:54 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Disposition to issuerStock Option (right to buy) · Derivative	4,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-22-054664 · doc4.xml · derivative · entry 6 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,985 Underlying: Common Stock · 4,000 shares Expires 2030-06-10 F2 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document
October 26, 2022 Filed Oct 26, 2022 21:54 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	4,000	$38.25	$153,000.00	Disclosure SEC source: 0001209191-22-054664 · doc4.xml · nonDerivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
October 26, 2022 Filed Oct 26, 2022 21:54 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	4,000	$16.00	$64,000.00	Disclosure SEC source: 0001209191-22-054664 · doc4.xml · nonDerivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 24, 2022 Filed Oct 26, 2022 21:54 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Disposition to issuerStock Option (right to buy) · Derivative	3,015	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-22-054664 · doc4.xml · derivative · entry 5 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,985 Underlying: Common Stock · 3,015 shares Expires 2030-06-10 F2 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document
October 24, 2022 Filed Oct 26, 2022 21:54 UTC	Vaxcyte, Inc. PCVX · Entity 1164	SaleCommon Stock	3,015	$35.11	$105,856.65	Disclosure SEC source: 0001209191-22-054664 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
October 24, 2022 Filed Oct 26, 2022 21:54 UTC	Vaxcyte, Inc. PCVX · Entity 1164	Exercise / conversionCommon Stock	3,015	$16.00	$48,240.00	Disclosure SEC source: 0001209191-22-054664 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 03, 2022 Filed Jun 7, 2022 17:38 UTC	Satsuma Pharmaceuticals, Inc. STSA · Entity 112442	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.46	$0.00	Disclosure SEC source: 0001567619-22-012476 · doc1.xml · derivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:31 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantStock Option (right to buy) · Derivative	18,750	$0.00 Strike: $22.70	$0.00	Disclosure SEC source: 0001209191-22-034061 · doc4.xml · derivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:31 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantCommon Stock	3,125	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034061 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:16 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	7,000	Not disclosed Strike: $9.22	Not disclosed	Disclosure SEC source: 0001209191-21-065719 · doc4.xml · derivative · entry 6 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2031-06-23 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:16 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	7,000	Not disclosed Strike: $11.88	Not disclosed	Disclosure SEC source: 0001209191-21-065719 · doc4.xml · derivative · entry 5 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.